Factor VIII-associated cellular stress
Research type
Research Study
Full title
Role of cellular stress signals in the immunogenicity of therapeutic factor VIII in patients with haemophilia A
IRAS ID
192996
Contact name
David Keeling
Contact email
Duration of Study in the UK
4 years, 5 months, 31 days
Research summary
Haemophilia A is a rare bleeding disorder caused by mutations in the gene encoding pro-coagulant factor VIII. The treatment, using a therapeutic factor VIII product can, in some patients with haemophilia, lead to the development of neutralizing anti-factor VIII antibodies. The reasons for the development of neutralizing anti-factor VIII antibodies are not clear. The aim of the study is to investigate whether some specific mutations in the gene encoding factor VIII are responsible for the initiation of the anti-factor VIII immune response. The information gained from the study may lead to improvements in the treatment of patients with haemophilia A in the future. This is an observational study, and will not alter or interfere with standard routine care.
REC name
East Midlands - Leicester South Research Ethics Committee
REC reference
16/EM/0153
Date of REC Opinion
13 Apr 2016
REC opinion
Further Information Favourable Opinion